| Literature DB >> 24745332 |
Sheng Xiao1, Nir Yosef2, Jianfei Yang3, Yonghui Wang4, Ling Zhou4, Chen Zhu1, Chuan Wu1, Erkan Baloglu3, Darby Schmidt3, Radha Ramesh3, Mercedes Lobera3, Mark S Sundrud3, Pei-Yun Tsai5, Zhijun Xiang4, Jinsong Wang4, Yan Xu4, Xichen Lin4, Karsten Kretschmer5, Peter B Rahl6, Richard A Young7, Zhong Zhong4, David A Hafler8, Aviv Regev9, Shomir Ghosh3, Alexander Marson10, Vijay K Kuchroo11.
Abstract
We identified three retinoid-related orphan receptor gamma t (RORγt)-specific inhibitors that suppress T helper 17 (Th17) cell responses, including Th17-cell-mediated autoimmune disease. We systemically characterized RORγt binding in the presence and absence of drugs with corresponding whole-genome transcriptome sequencing. RORγt acts as a direct activator of Th17 cell signature genes and a direct repressor of signature genes from other T cell lineages; its strongest transcriptional effects are on cis-regulatory sites containing the RORα binding motif. RORγt is central in a densely interconnected regulatory network that shapes the balance of T cell differentiation. Here, the three inhibitors modulated the RORγt-dependent transcriptional network to varying extents and through distinct mechanisms. Whereas one inhibitor displaced RORγt from its target loci, the other two inhibitors affected transcription predominantly without removing DNA binding. Our work illustrates the power of a system-scale analysis of transcriptional regulation to characterize potential therapeutic compounds that inhibit pathogenic Th17 cells and suppress autoimmunity.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24745332 PMCID: PMC4066874 DOI: 10.1016/j.immuni.2014.04.004
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745